Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario J N M Ouwens

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Research Synthesis Methods|June 11, 2015
Network meta-analysis of parametric survival curvesMario J N M Ouwens, Zoe Philips, Jeroen P Jansen
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival modelsShannon Cope, Mario J N M Ouwens, Jeroen P Jansen, et al.
Current Medical Research and Opinion|September 24, 2015
Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapyMario J N M Ouwens, Jos Nauta, Jean-Claude Ansquer, et al.
Biometrics|December 24, 2002
Maximin D-optimal designs for longitudinal mixed effects modelsMario J N M Ouwens, Frans E S Tan, Martijn P F Berger
Current Medical Research and Opinion|June 30, 2015
Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD studyOleg A Melnikov, Sergey V Lilenko, Jos Nauta, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 16, 2011
Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectivenessPatricia Guyot, Nicky J Welton, Mario J N M Ouwens, et al.
BMC Medical Research Methodology|February 3, 2012
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesPatricia Guyot, A E Ades, Mario J N M Ouwens, et al.
Pharmacoeconomics|May 19, 2019
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival ExtrapolationsMario J N M Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, et al.
Clinical Therapeutics|February 28, 2015
Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zosterKavi J Littlewood, Mario J N M Ouwens, Christophe Sauboin, et al.
The Oncologist|October 2, 2012
Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanomaPascale Dequen, Paul Lorigan, Jeroen P Jansen, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Research Synthesis Methods|June 11, 2015
Network meta-analysis of parametric survival curvesMario J N M Ouwens, Zoe Philips, Jeroen P Jansen
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival modelsShannon Cope, Mario J N M Ouwens, Jeroen P Jansen, et al.
Current Medical Research and Opinion|September 24, 2015
Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapyMario J N M Ouwens, Jos Nauta, Jean-Claude Ansquer, et al.
Biometrics|December 24, 2002
Maximin D-optimal designs for longitudinal mixed effects modelsMario J N M Ouwens, Frans E S Tan, Martijn P F Berger
Current Medical Research and Opinion|June 30, 2015
Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD studyOleg A Melnikov, Sergey V Lilenko, Jos Nauta, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 16, 2011
Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectivenessPatricia Guyot, Nicky J Welton, Mario J N M Ouwens, et al.
BMC Medical Research Methodology|February 3, 2012
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesPatricia Guyot, A E Ades, Mario J N M Ouwens, et al.
Pharmacoeconomics|May 19, 2019
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival ExtrapolationsMario J N M Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, et al.
Clinical Therapeutics|February 28, 2015
Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zosterKavi J Littlewood, Mario J N M Ouwens, Christophe Sauboin, et al.
The Oncologist|October 2, 2012
Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanomaPascale Dequen, Paul Lorigan, Jeroen P Jansen, et al.
Pageof 2